Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization

Quidel Corporation (

) (“Quidel”)

,

a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s Lyra? SARS-CoV-2 Assay has received expanded Emergency Use Authorization (EUA) claims from the Food and Drug Administration (FDA) to allow testing with three additional thermocyclers: Applied Biosystems 7500 Standard, Roche LightCycler 480, and Qiagen Rotor-Gene Q.

1

Acceptable Specimens Expanded to Include Nasal and Nasal Turbinate Swabs

Under the initial EUA, the Lyra? SARS-CoV-2 Assay real-time RT-PCR test was intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19 by their healthcare provider. The list of acceptable specimens has been expanded by the CDC to include nasal and nasal turbinate swabs. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests. EUAs allow for the early availability of important diagnostic tools “when there are no adequate, approved and available alternatives.”2

The Lyra? reagents include unique features that provide for simple transport and storage, improved workflow, shorter time to result, and other benefits that favorably affect diagnostic test outcome. The Lyra SARS-CoV-2 Assay provides these and certain additional advantages over many other tests currently on the market for this novel coronavirus, including easier set-up and faster time to result.

Quidel Receives CE Mark, Health Canada Authorization

Separately, the Lyra? SARS-CoV-2 Assay received CE-Mark on March 25, 2020. The CE Mark allows Quidel to market and sell the Lyra? SARS-CoV-2 Assay in Europe, as well as other countries that accept the CE Mark. Also, on March 25, 2020, Quidel received authorization from Health Canada to market and sell the assay in Canada. The assay is currently available for sale in the United States under EUA and can be purchased by laboratory professionals through Quidel directly, or through their Cardinal Health representative.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia?, QuickVue?, D3? Direct Detection, Thyretain?, Triage? and InflammaDry? leading brand names, as well as under the new Solana?, AmpliVue? and Lyra? molecular diagnostic brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza , respiratory syncytial virus , Strep A, herpes, pregnancy, thyroid disease and fecal occult blood . Quidel's recently acquired Triage? system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel’s comprehensive product portfolio, visit quidel.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation,fluctuations in our operating results resulting from the timing of the onset, length and severity of cold and flu seasons, seasonality, government and media attention focused on influenza and other respiratory viruses and the related potential impact on humans from such novel influenza or other respiratory viruses, adverse changes in competitive conditions, the reimbursement system currently in place and future changes to that system, changes in economic conditions in our domestic and international markets, lower than anticipated market penetration of our products, the quantity of our product in our distributors’ inventory or distribution channels, changes in the buying patterns of our distributors, and changes in the healthcare market and consolidation of our customer base; our development and protection of proprietary technology rights; our development of new technologies, products and markets; our reliance on sales of our influenza diagnostic tests; our reliance on a limited number of key distributors; our exposure to claims and litigation, including the ongoing litigation between the Company and Beckman Coulter, Inc.; intellectual property risks, including but not limited to, infringement litigation; our need for additional funds to finance our capital or operating needs; the financial soundness of our customers and suppliers; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; adverse actions or delays in new product reviews or related to currently-marketed products by the U.S. Food and Drug Administration (the “FDA”) or other regulatory authorities or loss of any previously received regulatory approvals or clearances; changes in government policies; costs of or our failure to comply with government regulations in addition to FDA regulations; compliance with government regulations relating to the handling, storage and disposal of hazardous substances; third-party reimbursement policies; our failure to comply with laws and regulations relating to billing and payment for healthcare services; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance; failures in our information technology or storage systems; our exposure to cyber-based attacks and security breaches; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with multiple product registration requirements, compliance with U.S. and foreign import/export laws, tariffs, exposure to currency exchange fluctuations and foreign currency exchange risk sharing arrangements, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, political and economic instability, increased financial accounting and reporting burdens. taxes, and diversion of lower priced international products into U.S. markets; changes in tax rates and exposure to additional tax liabilities or assessments; our ability to manage our growth strategy and identify and integrate acquired companies or technologies; risks relating to the acquisition and integration of the Triage and BNP Businesses; that we may have to write off goodwill relating to our acquisitions; the level of our indebtedness and deferred payment obligations; our ability to generate sufficient cash flow to meet our debt service and deferred payment obligations; that we may incur additional indebtedness; that the Senior Credit Facility is secured by substantially all of our assets; the agreements for our indebtedness place operating and financial restrictions on the Company; that an event of default could trigger acceleration of our outstanding indebtedness; increases in interest rate relating to our variable rate debt; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and the indenture governing our Convertible Senior Notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; and our intention of not paying dividends.Forward-looking statements typically are identified by the use of terms such as “may,” “will,” “should,” “might,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the “SEC”) from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.

___________________________________________________________________________________Applied Biosystems?, LightCycler? 480, and Rotor-Gene? are registered trademarks of their respective owners.https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Quidel公司(纳斯达克代码：QDEL)(“Quidel”)是快速诊断测试解�浮⒒谙赴牟《狙Х治肿诱锒舷低车墓┯ι蹋迹琎uidel的Lyra SARS-CoV-2检测已经�称泛鸵┪锕芾砭�(FDA)的扩�笔褂檬谌�(EUA)，允许对另外三种热循环�胁馐裕河τ蒙锵低�7500标准、Roche LightCycler 480和奇根基�。

可接受样本扩展至包括鼻及鼻甲拭子

在最�UA下，Lyra非典-CoV-2的实时RT-PCR检测是为了定性地检测SARS-CoV-2来自疑似COVID-19患者的鼻咽�适米友局械暮怂帷＜膊】刂浦行睦┐山邮苎镜那宓ィ呛捅羌资米影ㄔ谀凇２馐越诟�1988年临床实验室改进修正案(CLIA)认证的实验室，“美国法典”第42编第263 a节，以执行高复杂性测试。欧盟成员国允许在“没有适当、经批准和可用的替代办法”的情�≡缣峁┲匾恼锒瞎ぞ摺�

Lyra试剂包含独特的特性，这些特性提供了�拇浜痛娲ⅰ⒏慕墓ぷ⒏痰慕峁奔湟约捌渌哉锒喜馐越峁欣跋斓暮么Α＠忱堑�-CoV-2试验提供了这些和某些额外的优势，比许多其他测试目前市场上的这种新型冠状病毒，包括更容易建立和更快的时间产生。

基德尔�么緾E认证

另外，Lyra SARS-CoV-2试验于2020年3月25日收到CE-Mark。CE标记允许Quidel在欧洲以及其他接受CE标记的国家销售和销售Lyra SARS-CoV-2测试。此外，在2020年3月25日，基德尔�幽么康氖谌ǎ诩幽么酆拖鄹眉觳夥椒ā８梅治翱稍诿拦軪UA销售，可由实验室专业人员直接通过Quidel购�部赏ü涫嗷】荡砉郝/p>

关于基德尔公司

Quidel公司致力于通过开发诊断解�咐刺岣呷】岛透ｌ恚庑┙饩缚梢愿纳苹颊叩慕峁⑽＝∠低程峁┚美妗uidel的产品在Sofia、QuickVue、D3直接检测、Thyretain、Triage和InflammaDry领先品牌以及新的Solana、MagiVue和Lyra分子诊断品牌下销售，帮助检测和诊断许多关键疾病和�渲邪⒑篮习《尽trep A、、妊娠、甲状腺疾病和粪便隐血。Quidel最近�牟馐苑掷嘞低嘲ㄒ桓娴牟馐圆说ィ诨だ淼�(POC)提供快速、成本效益高的治疗�诟馐灾刑峁┎煌拿庖叻治ィ緽NP、CK-MB、d-二聚体、肌红蛋白、肌钙蛋白I和TOX定性药物筛选提供诊断�；露难蟹⒁婊乖诳⒁幌盗姓锒辖饩福酉冉拿庖叻治肿诱锒喜馐裕越徊教岣咭缴旃摇⒁皆汉筒慰际笛槭业囊搅票＝≈柿俊Ｓ泄豎uidel的综合产品组合的更多信息，请访问quidel.com。

前瞻性陈�>

本新闻稿载有联邦证券法所指的前瞻性声�婕爸卮铡⒓偕韬筒蝗范ㄒＰ矶嗫赡芊⑸氖录乜赡芑嵊跋煳颐俏蠢吹牟莆ê鸵导ǎ颐堑氖导式峁鸵导赡苡肭罢靶员ū碇锌赡苊枋凳镜慕峁鸵导ù锻ァＲ魏吻罢靶缘纳荒艿玫奖Ｖ�.实际结果和表现上的差异可能是由于�斐傻模�(但不限于)由于感冒和�窘诘目际奔洹⑹奔涑ざ毯脱现爻潭取⒓窘谛浴⒄兔教宥粤推渌啦《镜墓刈⒁约按死嘈滦土啦《径匀死嗟南喙厍痹谟跋臁⒕赫牟焕浠⑾中械某セ怪贫群臀蠢炊愿弥贫鹊母谋洹⒐诤凸适谐【米纯浠⑽夜返氖谐∩嘎实陀谠て诘纫斐傻牟ǘ颐堑牟吩诜窒痰目獯婊乐械氖浚颐欠窒痰墓郝降谋浠搅剖谐〉谋浠臀颐堑目突旱墓蹋晃颐强⒑捅；ぷɡ际晃颐强⑿录际虏泛褪谐。晃颐且览涤诹锒喜馐缘南郏晃颐嵌杂邢奘康闹窒痰囊览担晃颐敲媪偎退咚系姆缦眨ǜ霉居氡纯寺舛毓局湔诮械乃咚希恢恫ǚ缦眨ǖ幌抻�, 侵权诉讼；我们需要额外资�阄颐堑淖时净晃颐堑目突Ш凸┯ι痰牟莆茫晃颐堑牟繁灰缴推渌＝√峁┱呓邮埽挥肫渌锒喜饭┯ι叹赫恍虏飞矫娴牟焕卸朊拦称泛鸵┪锕芾砭�(“FDA”)�喙艿本帜壳跋鄣牟酚泄氐男形ヒ郧盎募喙苄砜苫桑徽叩谋浠怀称泛鸵┢饭芾砭痔猓叩姆延没娑ǖ那榭氪怼⒋⒋婧痛χ梦Ｏ瘴镏视泄氐恼坏谌奖ㄏ撸晃颐俏茨茏泄乇＝》ズ透犊畹姆珊吞晃颐锹悴沸枨芰Γ辉牧瞎┯χ卸希徊啡毕荩槐Ｏ瘴春堑囊滴眨晃颐堑男畔⒓际娲⑾低彻收希晃颐敲媪倩谕绲墓セ踩┒矗还芾聿愫凸丶嗽钡木赫退还史缦眨ǖ幌抻谧嘀植返羌且拦屯夤伞⒐厮啊⒒懵什ǘ屯饣惴缦辗值０才拧⒏犊钪芷谘映ぁ⑾奂鄹秃陀κ照丝钍占讯燃哟恫ū；ぜ⒄魏途貌晃榷ā⒉莆坪捅ǜ娓旱Ｔ８乘�, 以及将价�偷墓什纷频矫拦谐。凰奥实谋浠约岸远钔馑笆崭赫赖某冢晃颐枪芾碓铰砸约笆侗媳皇展汗净芰Γ挥胧展汉驼戏掷嗪桶屠枰幸滴氐姆缦眨晃颐强赡懿坏貌蛔⑾胛颐堑氖展河泄氐纳逃晃颐堑母赫脱悠谥Ц兑逦剑晃颐怯心芰Σ愎坏南纸坷绰男形颐堑某フ脱悠谥Ц兑逦颐强赡芑岵钔獾母赫桓呒缎糯浦峭ü颐撬械淖什吹１５模晃颐堑恼槎怨旧柚昧司筒莆疲晃ピ际录赡艿贾挛颐堑奈闯フ僭挥胛颐堑目杀淅收氐睦噬仙挥捎诮颐堑墓杀径斐傻南∈停还善奔鄹ǘ晃颐堑陌募⑻乩莘珊凸赜诳勺桓呒镀本莸钠锌赡芡瞥倩啥蜕桃岛喜⒒平灰撞扇⌒卸墓娑ǎ晃颐遣恢Ц杜上⒌囊馔肌Ｇ罢靶猿率Ｊ怯谩翱赡堋薄ⅰ耙庵尽薄ⅰ坝Ω谩薄ⅰ翱赡堋薄ⅰ霸て凇薄ⅰ霸て凇薄ⅰ肮兰啤薄ⅰ凹苹薄ⅰ耙庠浮薄ⅰ澳勘辍薄ⅰ跋钅俊薄ⅰ罢铰浴薄ⅰ拔蠢础焙屠嗨频拇视锢词侗」苡行┣罢靶缘谋硎Ｎ颐遣皇毕灰孜被�(“证券交易委员会”)提交的报告和登记声�缦沼Φ玫饺险婵悸恰Ｎ颐翘嵝涯悴灰忠览嫡庑┣罢靶缘纳 只反映了截至本新闻稿发布之日管理层的分�晒娑ㄍ猓颐敲挥幸逦颊庑┣罢靶陨魏涡薅┗陆峁蘼凼怯捎谛碌男畔ⅰ⑽蠢词录/p>

__Applied生物系统，LightCycler 480，和旋翼-基�wners.https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization的注册商标

免�形姆胗商谘斗刖峁┲С郑煌径苑胄畔⒌淖既沸曰啃运斐傻娜魏嗡怀械Ｈ魏卧�